Trials / Approved For Marketing
Approved For MarketingNCT04729062
C3G/Primary IC-MPGN EAP
US Early Access Program for the Treatment of Patients With C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis With Pegcetacoplan
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Apellis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- —
Summary
This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with C3G and Primary IC-MPGN.
Conditions
- C3G
- IC-MPGN
- C3 Glomerulopathy
- C3 Glomerulonephritis
- Complement 3 Glomerulopathy
- Complement 3 Glomerulopathy (C3G)
- Complement 3 Glomerulonephritis
- Dense Deposit Disease
- DDD
- Membranoproliferative Glomerulonephritis
- Membranoproliferative Glomerulonephritis (MPGN)
- Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegcetacoplan | Complement (C3) Inhibitor |
Timeline
- First posted
- 2021-01-28
- Last updated
- 2025-11-06
Source: ClinicalTrials.gov record NCT04729062. Inclusion in this directory is not an endorsement.